Cell & Gene Therapy CRO Services for Biotech and Pharmaceutical Companies
Evestia Clinical helps biotechnology and pharmaceutical companies advance Cell & Gene Therapy programs through integrated scientific expertise, manufacturing coordination and regulatory leadership from Phase I to global registration.
Advanced Therapy Development Built Around Biotech Companies
Advanced therapy development rewards manufacturing integration, multidisciplinary scientific collaboration and experienced regulatory leadership embedded from the earliest stages of program planning. Consistent senior program leadership throughout delivery is central to this approach.
Evestia Clinical works as an integrated scientific partner throughout clinical development, providing expertise across Clinical Operations, Medical Affairs, Regulatory Affairs, Biostatistics and Clinical Data Management, through our Full-Service CRO model or embedded specialists via FSP Solutions.
Experienced Advanced Therapy Medical Specialists
Direct access to scientists with hands-on Phase I–IV & Post-Marketing experience across CAR-T, gene replacement therapies, ATMPs and regenerative medicine.
Senior Program Leadership
Senior-led delivery throughout program execution. Faster decisions, clearer communication and greater program confidence at every milestone.
Integrated Full-Service Expertise
Clinical Operations, Medical Affairs, Regulatory Affairs, Biostatistics, Medical Writing and Pharmacokinetics working as one coordinated advanced therapy team.
Flexible FSP and CRO Models
Full-Service CRO and FSP Solutions providing scalable expertise aligned with program requirements and manufacturing timelines.
Cell & Gene Therapy Expertise at a Glance
These figures represent direct program experience across CAR-T, gene replacement, oncology cell therapies and regenerative medicine, informing every manufacturing, regulatory and operational decision Evestia Clinical makes.
50+
Cell & Gene Therapy Studies Supported
Across diverse advanced therapy modalities
Oncology
Expertise
CAR-T and cell-based cancer therapies
Rare Disease
Development Experience
Genetic disorder gene therapy programs
Phase I–IV
Clinical Development Support
First-in-human through post-marketing
Scientific Considerations in Cell & Gene Therapy Development
Manufacturing integration, chain of identity management, specialist site qualification and long-term follow-up planning are central to successful advanced therapy development. Integrated multidisciplinary planning across manufacturing, clinical, regulatory and scientific functions supports confident program delivery from the outset.
Patient-specific manufacturing creates interdependencies between manufacturing availability and site scheduling that require coordinated planning from the earliest stages of program design. Temperature-controlled supply chains and product logistics are integral to operational strategy. Our Global CRO capabilities support complex advanced therapy programs across Phase I, Phase II and Phase III. Key program considerations include:
Developing Advanced Therapies Requires Scientific Expertise, Operational Precision and Seamless Coordination
Successful Cell & Gene Therapy development depends on integrated manufacturing coordination, specialist investigator networks, regulatory planning and multidisciplinary scientific collaboration from protocol development through global registration. Each advanced therapy modality brings distinct scientific, operational and regulatory requirements that benefit from therapeutic understanding embedded throughout the program.
Cell & Gene Therapy expertise at Evestia Clinical is integrated with Oncology CRO, Rare Disease CRO, Immunology CRO and Neurology CRO capabilities. Clinical Trial Management, Medical Affairs, Regulatory Affairs, Clinical Data Management and Pharmacovigilance work within one coordinated team throughout every program.
Advanced Therapy Medicinal Products (ATMPs)
ATMPs require development strategies, manufacturing processes and regulatory pathways that require specialized development strategies and regulatory planning, distinct from traditional pharmaceutical development. Regulatory requirements span EMA's Committee for Advanced Therapies (CAT), FDA's Center for Biologics Evaluation and Research (CBER) and MHRA guidance. ATMP classification, IMPD preparation and country-specific frameworks add complexity at every stage of development.
Early regulatory strategy is one of the most valuable strategic decisions an ATMP sponsor can make. Engaging with accelerated pathways, including RMAT designation (US), PRIME (EU), Fast Track and Breakthrough Therapy Designation, from the earliest stages of development can significantly improve timelines and the quality of regulatory interactions throughout the program. Evestia Clinical's Regulatory Affairs teams help sponsors identify and maximize these opportunities as part of an integrated development strategy.
ATMP categories include:
- Gene Therapy Medicinal Products (GTMPs): recombinant nucleic acid-based therapies
- Somatic Cell Therapy Medicinal Products (SCTMPs): modified human cell therapies
- Tissue-Engineered Products (TEPs): engineered cell and tissue therapies
- Regenerative Medicine approaches targeting tissue repair and replacement
Supporting Gene Therapy Clinical Development
Gene therapies are creating new opportunities to address the underlying causes of disease by replacing, modifying or repairing genetic material. These programs typically involve complex vector manufacturing, specialized regulatory requirements and long-term patient follow-up obligations that benefit from integrated scientific, operational and regulatory expertise throughout development.
Gene editing approaches including CRISPR technologies, RNA therapeutics and next-generation vector platforms are expanding the range of conditions that gene-based interventions can address. Evestia Clinical supports sponsors developing gene replacement therapies, gene editing programs, viral vector therapies and RNA-based approaches through integrated clinical development support aligned with manufacturing quality and regulatory requirements.
Many gene therapy programs target rare genetic diseases or neurological conditions with significant unmet medical need, enabling sponsors to benefit from orphan designation and accelerated regulatory pathways alongside specialist gene therapy development capability.
Supporting CAR-T and Personalized Cell Therapy Programs
CAR-T therapies and personalized cell therapies present some of the most operationally complex challenges in modern clinical development. Vein-to-vein logistics, from patient apheresis through manufacturing, release, cold-chain transport and clinical administration, require meticulous multidisciplinary coordination across multiple stakeholders. Chain of identity processes must remain unbroken throughout. Decentralized manufacturing models are emerging but introduce new coordination requirements alongside the established complexity of centralized autologous programs.
Commercial readiness, product traceability and manufacturing-clinical coordination planned from the earliest program stages supports efficient program progression, manufacturing readiness and regulatory success. Experience spans autologous and allogeneic programs targeting hematological malignancies and solid tumors, with Oncology CRO expertise integrated throughout.
What Are Cell & Gene Therapies?
Cell and gene therapies are advanced therapies designed to modify, replace or repair cellular and genetic functions within the body. Both approaches have created new opportunities to treat diseases that were previously considered untreatable.
Cell Therapy
Cell therapies involve administering living cells to patients to treat or manage disease. Examples include:
- CAR-T therapies
- Stem cell therapies
- Immune cell therapies
- Regenerative medicine approaches
Gene Therapy
Gene therapies aim to modify or replace genetic material to address the underlying cause of disease. These may include:
- Viral vector therapies
- Gene replacement therapies
- Gene editing technologies
- RNA-based therapies
Our Cell & Gene Therapy Clinical Trial Services
Integrated manufacturing coordination, multidisciplinary scientific collaboration and aligned regulatory support sustain program quality across the long timelines of advanced therapy development. Every service below is delivered within one integrated team, aligned towards the same program outcome.
Clinical Trial Management
Providing program leadership, strategic oversight and operational management across complex advanced therapy studies from initiation through close-out.
Learn moreClinical Operations
Integrated clinical operations across advanced therapy programs, coordinating investigators, manufacturing sites, vendors and study activities throughout the development lifecycle.
Learn moreClinical Monitoring
Supporting specialist sites through intensive monitoring, quality oversight and protocol compliance activities for cell and gene therapy programs.
Learn moreClinical Site Management
Helping sponsors identify, qualify and activate experienced cell and gene therapy investigator sites with appropriate infrastructure and expertise.
Learn moreStudy Start-Up Services
Accelerating site feasibility, qualification and activation to reduce timelines from protocol development to first patient treated in advanced therapy studies.
Learn moreRegulatory Affairs
Supporting advanced therapy regulatory strategies, ATMP-specific submissions and authority interactions with FDA, EMA, MHRA and other global regulators.
Learn moreClinical Data Management
Managing complex datasets, biomarker information, manufacturing data integration and long-term follow-up data with CDISC-compliant outputs.
Learn moreBiostatistics
Providing advanced statistical planning, endpoint analysis and submission-ready reporting support for advanced therapy programs including novel designs.
Learn moreMedical Affairs
Learn morePharmacovigilance
Delivering specialized safety oversight for advanced therapy programs including long-term follow-up safety reporting and SUSAR management.
Learn moreMedical Writing
Preparing protocols, investigator brochures, Clinical Study Reports, IMPD documentation and regulatory submissions for advanced therapy programs.
Learn morePharmacokinetics
Supporting PK/PD modeling and biodistribution assessments for viral vectors, cell therapies and other advanced therapy products.
Learn moreFSP Solutions
Dedicated embedded advanced therapy specialists available through our Functional Service Provider model for sponsors requiring flexible specialist resource scaling.
Learn moreExpertise Across Advanced Therapy Modalities
CAR-T and Cell-Based Therapies
Supporting development programs involving engineered CAR-T cell therapies, personalized cell treatments and other immune cell-based approaches targeting hematological and solid tumor malignancies.
Learn moreGene Replacement Therapies
Helping sponsors develop viral vector-based and non-viral gene replacement therapies targeting the underlying genetic causes of rare diseases and inherited disorders.
Learn moreRare Genetic Disorders
Combining Rare Disease and Cell & Gene Therapy expertise to support highly specialized programs for rare inherited conditions requiring advanced therapy approaches.
Learn moreOncology Cell Therapies
Supporting innovative cell-based therapies targeting solid tumors and hematological malignancies, combining Cell & Gene Therapy operational expertise with our Oncology CRO capabilities.
Learn moreRegenerative Medicine
Providing operational support for programs focused on tissue repair, tissue-engineered products and regenerative medicine approaches for conditions with limited therapeutic options.
Supporting Advanced Therapy Programs from Early Development Through Regulatory Submission
Scientific continuity, manufacturing integration and regulatory alignment established in Phase I shape every subsequent development decision. Phase I centers on manufacturing coordination, site qualification, safety monitoring and early proof-of-mechanism.
Phase II demands refined manufacturing processes, biomarker-driven patient selection and adaptive design strategies. Long-term follow-up planning and pharmacovigilance frameworks embedded at this stage strengthen program quality, regulatory readiness and successful Phase III progression.
The same teams adapt manufacturing coordination and regulatory planning as programs mature. Regulatory Affairs and Clinical Trial Management are aligned from the outset, carrying scientific and regulatory continuity from Phase I through Phase II into Phase III registration.
Cell & Gene Therapy Development Across Every Phase
Phase I advanced therapy programs demand intensive safety monitoring, manufacturing integration and specialist site qualification alongside first-in-human dose escalation. Early-stage operational precision protects product integrity, patient safety and the regulatory confidence that subsequent development depends on.
Learn moreProof-of-concept studies require refined manufacturing processes, biomarker-driven patient stratification and clear exposure-response strategies. Adaptive designs and precision medicine approaches maximize the value of Phase II data for regulatory positioning and commercial planning ahead of pivotal studies.
Learn morePivotal registration programs introduce global site coordination, multinational regulatory submissions and the long-term follow-up infrastructure that health authorities require. Our Global CRO capabilities help sponsors access specialist advanced therapy treatment centers and maintain consistent operational quality across international programs.
Learn moreHow Evestia Strengthens Cell & Gene Therapy Development
Integrated manufacturing coordination, collaborative scientific delivery and consistent advanced therapy expertise support program confidence, manufacturing excellence and regulatory success throughout development.
Manufacturing Coordination
Integrating manufacturing timelines with clinical schedules and site logistics is one of the most demanding aspects of advanced therapy development. Planning this coordination from program initiation supports continuous program progression through integrated manufacturing and clinical coordination at every stage.
Chain of Identity and Chain of Custody
Patient-specific therapies require unbroken documentation from apheresis through manufacturing, release and administration. Chain of identity and chain of custody frameworks must be embedded from the earliest operational planning stages to protect product integrity and regulatory confidence.
Specialist Investigator Sites
Advanced therapy programs require sites with specialist infrastructure, qualified staff and validated processes. Connecting sponsors with appropriate treatment centers and providing rigorous site qualification support supports efficient site qualification and activation through established advanced therapy expertise.
Long-Term Follow-Up
Gene therapy programs typically require patient follow-up extending 10 to 15 years post-treatment. Building operational infrastructure, data collection systems and pharmacovigilance frameworks at the outset strengthens long-term program quality, patient follow-up and regulatory readiness.
Global ATMP Development
ATMPs face distinct regulatory requirements across FDA, EMA and other global health authorities. ATMP classification, IMPD preparation and country-specific frameworks require coordinated planning across global markets. Integrated regulatory strategy and global operational capability support coordinated multinational advanced therapy development through integrated regulatory and operational expertise.
Scalable Cell & Gene Therapy Expertise
As advanced therapy portfolios grow, embedded scientific leadership and integrated partnership across manufacturing coordination, regulatory affairs and clinical operations become a strategic priority. Full-Service CRO delivery and Functional Service Provider (FSP) specialists provide the depth and program flexibility needed at each development stage.
Oncology, Rare Disease and Cell & Gene Therapy Expertise Combined
Oncology CAR-T, rare genetic disease gene replacement and neurological gene therapies each require integrated knowledge across both advanced therapy development and the specific therapeutic context, delivered through one coordinated multidisciplinary scientific team. Combining Immunology CRO capabilities with Cell & Gene Therapy expertise supports immuno-oncology ATMP programs. Orphan Drug Development expertise maximizes regulatory incentives for rare disease gene therapy programs. Neurology CRO expertise supports gene therapies targeting neurological and neurodegenerative conditions. This integrated capability covers:
- Oncology CRO
- Rare Disease CRO
- Immunology CRO
- Neurology CRO
- Orphan Drug Development
- Precision medicine and biomarker-driven development
- Regenerative medicine programs
Why Sponsors Choose Evestia Clinical for Cell & Gene Therapy Development
The advanced therapy CRO a sponsor chooses shapes more than operational execution. It shapes manufacturing confidence, regulatory strategy quality, site network capability and the program momentum that investor and board confidence depends on. As a specialist Biotech CRO, Evestia Clinical is structured to provide the scientific depth, senior access and operational agility that complex advanced therapy programs demand.
Cell & Gene Therapy Knowledge Embedded in Every Program
Dedicated Cell & Gene Therapy teams with direct experience across CAR-T, gene replacement therapies, viral vector approaches, ATMPs and regenerative medicine, providing experienced scientific leadership throughout program delivery.
Oncology and Rare Disease Experience
Integrated Oncology CRO and Rare Disease CRO expertise that extends Cell & Gene Therapy capabilities into the most clinically important advanced therapy indications, from oncology CAR-T to rare genetic disease gene replacement.
Supporting Global Regulatory Success
Specialist ATMP regulatory expertise covering EMA CAT submissions, FDA CBER interactions, RMAT and PRIME designations, IMPD preparation, long-term follow-up requirements and global advanced therapy development strategy.
Delivering Global Advanced Therapy Programs
Established specialist treatment centers and multinational operational experience enable sponsors to access qualified advanced therapy sites and coordinate international cell and gene therapy programs through established investigator networks and coordinated global program leadership.
A Scientific Partner Built for Biotechnology Companies
Senior-led program delivery, direct communication and integrated scientific collaboration give biotechnology organizations the responsiveness they need to support confident program progression and informed development decisions throughout the lifecycle.
Flexible Partnerships That Scale With Your Program
Advanced therapy programs supported through our Full-Service CRO model or via dedicated specialist resource through FSP Solutions, providing flexibility to scale expertise as program requirements and program evolution demand.
Scalable Embedded Advanced Therapy Expertise
Dedicated advanced therapy specialists available through FSP Solutions, providing experienced CRAs, trial managers and scientific professionals embedded within sponsor teams as scalable embedded Cell & Gene Therapy expertise aligned with sponsor requirements.
Cell & Gene Therapy CRO Support for Biotech Companies
Biotechnology companies advancing Cell & Gene Therapy programs benefit from manufacturing partnerships, integrated scientific collaboration and scalable expertise that grows alongside each program. Long-term collaborative partnership across manufacturing coordination, regulatory affairs and clinical operations supports confident advanced therapy development at every stage.
Evestia Clinical provides integrated scientific partnership supporting Cell & Gene Therapy programs from Phase I through registration. Available through our Full-Service CRO model or embedded FSP specialists, and structured as a dedicated Biotech CRO, the partnership adapts as programs evolve and manufacturing requirements change.
Frequently Asked Questions About Cell & Gene Therapy CRO Services
Explore Related Clinical Development Services
Service Pages
Development Phases
Related Therapeutic Expertise
Helping Advanced Therapy Innovators Transform Patient Care
Manufacturing coordination, integrated scientific expertise and collaborative partnership from first-in-human studies to global registration. Evestia Clinical supports biotechnology and pharmaceutical companies advancing CAR-T, gene replacement, ATMP and regenerative medicine programs with the scientific depth that successful advanced therapy development requires.